Tumor-agnostic drug development in dMMR/MSI-H solid tumors
Drug Development
European Journal of Cancer
Pooled Safety Analysis of Single-Agent Lurbinectedin in Patients With Advanced Solid Tumours
Nature
Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results
Annals of Oncology
Weight Gain in Cancer Patients Treated with Brain Penetrant RET-selective Inhibitors
Nature Medicine
Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results
Investigational New Drugs
A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors
Nature
In situ tumour arrays reveal early environmental control of cancer immunity
Investigational New Drugs
A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors
Journal of Clinical Oncology
Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation
ASCO Education Book
Rise of Antibody-Drug Conjugates: The Present and Future